Septerna, Inc.
Financials
Valuation Metrics
Septerna, Inc.'s Market Cap is $1.84B. At end of 2025 it was $1.23B. Ranked #2087 of 3,121 in US market (top 67%), #812 of 1,463 on NASDAQ (top 56%), #148 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.84B | US#2,087/3,121 Sec#148/266 |
| Revenue | $99M | US#2,706/3,121 Sec#127/266 |
| Net Income | $-24M | US—/3,121 Sec—/266 |
| Total Assets | $567M | US#2,723/3,121 Sec#148/266 |
| Net Assets | $387M | US#2,396/3,121 Sec#138/266 |
| Employees | 123 | US#2,590/3,121 Sec#164/266 |
| Value | ||
| P/B | 4.77x | US#2,181/3,121 Sec#136/266 |
| P/S | 18.65x | US#2,831/3,121 Sec#141/266 |
| FCF Yield | 5.70% | US#1,274/3,121 Sec#42/266 |
| Profitability | ||
| ROE | -6.27% | US#2,295/3,121 Sec#74/266 |
| ROA | -4.28% | US#2,493/3,121 Sec#84/266 |
| Op. Margin | -44.04% | US#2,673/3,121 Sec#109/266 |
| Revenue Growth | 13520.11% | US#5/3,121 Sec#3/266 |
| Financial Health | ||
| Debt Ratio | 46.55% | US#528/3,121 Sec#139/266 |
| Total Debt | $23M | US#2,740/3,121 Sec#186/266 |
| FCF | $105M | US#1,717/3,121 Sec#61/266 |
| Cash | $85M | US#2,317/3,121 Sec#186/266 |
| Current Ratio | 4.99x | US#474/3,121 Sec#147/266 |
| Performance | ||
| 1Y Return | 174.50% | US#81/3,121 Sec#29/266 |
| 1M Return | -9.82% | US#2,418/3,121 Sec#183/266 |
| From 52W High | -22.70% | US#1,669/3,121 Sec#127/266 |
| 1Y MDD | -25.18% | US#1,066/3,121 Sec#54/266 |
| Trading | ||
| Volume | 212,788 shares | US#2,602/3,121 Sec#250/266 |
| Trading Value | $8M | US#2,434/3,121 Sec#202/266 |
| Per Share | ||
| EPS | $-0.52 | US—/3,121 Sec—/266 |
| BPS | $8.29 | US#1,971/3,121 Sec#83/266 |
Company Info
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.